Evotec is a drug discovery alliance and development partnership company. It provides pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capital firms with drug discovery solutions in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company specializes in the areas of neuroscience, diabetes, complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis.
Type | Public | |
Founded | 1993 | |
HQ | Hamburg, DE | Map |
Website | evotec.com | |
Employee Ratings |
EUR | |
---|---|
Revenue (Q1, 2022) | 164.7m |
Gross profit (Q1, 2022) | 50.8m |
Net income (Q1, 2022) | (73.2m) |
EBITDA (Q1, 2022) | (66.4m) |
EBIT (Q1, 2022) | (66.1m) |
Market capitalization (29-Jun-2022) | 4.1b |
Closing stock price (29-Jun-2022) | 23.6 |
Cash (31-Mar-2022) | 660.5m |
EV | 4.0b |
EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 375.4m | 446.4m | 500.9m | 618.0m |
Cost of goods sold | (232.1m) | (264.7m) | (303.1m) | (400.9m) |
Gross profit | 214.6m | 258.2m | 270.0m | 290.6m |
R&D expense | (35.6m) | (58.4m) | (63.9m) | (72.2m) |
EUR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 103.8m | 103.2m | 114.3m | 119.4m | 111.6m | 129.4m | 133.1m | 138.2m | 159.7m | 164.7m |
Cost of goods sold | (61.3m) | (59.7m) | (66.6m) | (71.5m) | (78.0m) | (121.7m) | (83.3m) | (102.6m) | (145.6m) | (132.4m) |
Gross profit | 61.0m | 61.0m | 65.8m | 64.8m | 51.7m | 27.2m | 66.1m | 55.5m | 31.6m | 50.8m |
R&D expense | (14.4m) | (14.9m) | (12.0m) | (15.1m) | (14.7m) | (16.3m) | (18.5m) | (17.0m) | (18.0m) | (18.1m) |
EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 109.1m | 277.0m | 422.6m | 699.3m |
Accounts Receivable | 45.9m | 82.3m | 79.0m | 132.1m |
Prepaid Expenses | 22.3m | 31.9m | 31.0m | 42.6m |
Inventories | 5.7m | 10.7m | 13.6m | 25.8m |
EUR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|
Cash | 111.6m | 322.3m | 249.6m | 285.4m | 224.4m | 215.9m | 401.6m | 382.3m | 333.4m | 660.5m |
Accounts Receivable | 48.8m | 51.6m | 51.8m | 68.2m | 90.8m | 94.4m | 115.5m | 77.0m | 90.1m | 93.8m |
Prepaid Expenses | 16.1m | 19.5m | 20.1m | 16.2m | 12.9m | 15.0m | 14.3m | 19.2m | 21.6m | 16.3m |
Inventories | 5.6m | 6.5m | 12.2m | 10.9m | 10.6m | 11.7m | 15.2m | 17.3m | 22.5m | 26.1m |
EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | 84.1m | 37.2m | 6.3m | 215.5m |
Depreciation and Amortization | 31.4m | 50.1m | 56.2m | 70.4m |
Inventories | (283.0k) | (1.4m) | (3.6m) | (11.7m) |
Accounts Payable | 5.0m | (2.0m) | 2.2m | 31.3m |
EUR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 13.1m | 10.7m | 29.7m | 17.1m | 7.3m | 5.8m | 52.7m | 112.7m | 247.0m | (73.2m) |
EUR | FY, 2018 |
---|---|
Revenue/Employee | 153.7k |
Company Name | Date | Deal Size |
---|---|---|
GlaxoSmithKine's the Verona site | January 07, 2021 | |
Just-Evotec Biologics | May 20, 2019 | $90 m |
Aptuit | July 30, 2017 | $300 m |
Cyprotex | October 26, 2016 | £55.7 m |
Euprotec | May 28, 2014 | $3.2 m |
Bionamics GmbH | March 24, 2014 | |
Cell Culture Service GmbH | January 03, 2013 | €1.2 m |
Compound Focus | June 01, 2011 | |
KINAXO Biotechnologies | April 19, 2011 | |
Develogen AG | July 14, 2010 |
Evotec revenue breakdown by business segment: 76.2% from EVT EXECUTE and 23.8% from EVT INNOVATE
Evotec revenue breakdown by geographic segment: 7.6% from GERMANY, 16.9% from UNITED KINGDOM, 15.9% from REST OF WORLD, 54.6% from UNITED STATES and 4.9% from Other
Evotec has 3.41k Twitter Followers. The number of followers has increased 2.6% month over month and increased 7.3% quarter over quarter
2.3k
Tweets
142
Following
3.4k
Followers
34
Tweets last 30 days
3.8
Avg. likes per Tweet
97.1%
Tweets with engagement
When was Evotec founded?
Evotec was founded in 1993.
Who are Evotec key executives?
Evotec's key executives are Werner Lanthaler, Craig Johnstone and Enno Spillner.
How many employees does Evotec have?
Evotec has 4,354 employees.
What is Evotec revenue?
Latest Evotec annual revenue is €618 m.
What is Evotec revenue per employee?
Latest Evotec revenue per employee is €141.9 k.
Who are Evotec competitors?
Competitors of Evotec include Eurofins, WuXi Biologics and Actelion Pharmaceuticals.
Where is Evotec headquarters?
Evotec headquarters is located at Essener Bogen 7, Hamburg.
Where are Evotec offices?
Evotec has offices in Hamburg, Göttingen, Köln, Neuried and in 9 other locations.
How many offices does Evotec have?
Evotec has 13 offices.
Receive alerts for 300+ data fields across thousands of companies